Technological advancements in the North America Multiple Sclerosis Therapeutics industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transforming industry practices, offering a comprehensive outlook on future opportunities and market potential.

The global multiple sclerosis therapeutic market size exceeded USD 26.53 billion in 2024 and is projected to expand at a CAGR of more than 4.9%, crossing USD 49.41 billion by 2037. North America industry is poised to account for largest revenue share of 45.7% by 2037, owing to well-developed healthcare facilities in the region.

Technological advancements in the North America Multiple Sclerosis Drugs Treatment industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transforming industry practices, offering a comprehensive outlook on future opportunities and market potential.

The size and share of the market is categorized based on Type (Drug Treatment, Physical Therapy) and Application (Hospital, Clinic, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The global multiple sclerosis drug market size is projected to grow from USD 25.07 billion to USD 42.07 billion, demonstrating a CAGR of over 4.2% during the forecast timeline, between 2025 and 2037. North America industry is anticipated to hold largest share by 2037, impelled by rising burden of multiple sclerosis among the population and a higher probability of women getting multiple sclerosis in the region.

The market size of the Stem Cell Therapy For Multiple Sclerosis Market is categorized based on Type (Intravenous, Intracerebroventricular) and Application (Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS)) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

Snapshot img

Neurodegenerative Diseases Therapeutics Market Size 2024-2028

The neurodegenerative diseases therapeutics market size is forecast to increase by USD 21.29 billion at a CAGR of 8.51% between 2023 and 2028.

The market is experiencing significant growth due to the strong drug development pipeline and the increasing aging population. However, the lack of disease-modifying therapies poses a major challenge. To address this challenge, advancements in technology are being explored, such as the integration of virtual assistants and automation in healthcare. For instance, robotic vacuum cleaners and window cleaning robots are being used to assist in daily chores, freeing up time for caregivers. These devices employ advanced sensors and suction technology, including magnets and a two-step cleaning process, to ensure thorough cleaning of surfaces. Remote controllers enable users to operate these devices with ease, further enhancing their convenience. As smart homes become more prevalent, the integration of these technologies with healthcare systems is expected to revolutionize care for neurodegenerative disease patients.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, continue to pose significant challenges in healthcare. While there is ongoing research for effective therapeutics, the focus on improving the quality of life for patients has led to an increase in demand for assistive technologies. The residential sector, including suction mechanism sector with brushes and wipers, and the battery-powered sector, have seen growth in the automatic cleaning industry. Robotic vacuum cleaners with advanced sensors and compatibility for various floor types have gained popularity. Additionally, window cleaning robots with suction, magnets, and two-step cleaning processes have emerged. These robotic cleaners and floor cleaning robots offer remote control features, making them convenient for users.



Industrialization activities and building constructions have led to an increased need for cleaning robots in commercial settings. The automatic cleaning industry is expected to grow, driven by the increasing demand for efficient and effective cleaning solutions. Dirt and dust on glass surfaces can also be addressed with the help of advanced sensors and polishing technologies in window cleaning robots.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Indication

  Multiple sclerosis
  Alzheimers disease
  Parkinsons disease
  Huntingtons disease
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Indication Insights

The multiple sclerosis segment is estimated to witness significant growth during the forecast period.

The market, particularly in the segment for Multiple Sclerosis (MS), is witnessing significant growth due to the increasing prevalence of this disease. In the US alone, approximately 1 million people are affected by MS, while globally, around 2.9 million individuals are diagnosed with this condition. To cater to this growing population, key companies are actively investing in research and development of novel therapeutics. Advanced technologies, such as Artificial Intelligence (AI), the Internet of Things (IoT), micro-electromechanical systems, sensors, vision technologies, robotics innovation, and cleaning robots, are being leveraged to develop interoperable solutions for MS patients. These technologies enable the creation of smart speakers, visualization equipment, and low-cost cleaning robots, enhancing the quality of life for patients.

Furthermore, the commercial section of this market is expected to experience strong growth during the forecast period as these advanced technologies and innovative drugs, such as Tecfidra, Aubagio, Lemtrada, Gilenya, and Tysabri, come to market.

Get a glance at the market report of share of various segments Request Free Sample

The Multiple sclerosis segment was valued at USD 14.44 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

The market in North America holds the largest market share in 2023, driven by the presence of prominent players. Key products in this category include T

In 2022, the value of multiple sclerosis (MS) treatments in Europe amounted to around 5.9 billion U.S. dollars. According to some projections, the market could reach some 8.7 billion dollars by 2028. Among world regions, North America represented by far the largest market for MS treatments.

Snapshot img

Neurologic Disorders Therapeutics Market Size 2024-2028

The neurologic disorders therapeutics market size is forecast to increase by USD 27.2 billion at a CAGR of 4.49% between 2023 and 2028.

Neurologic disorders, such as Parkinson's disease, Alzheimer's disease, and epilepsy, continue to pose significant challenges for the healthcare industry. The market is experiencing strong growth, driven by several key trends. The approval of novel drugs, including gene therapies and monoclonal antibodies, is revolutionizing the treatment landscape. Additionally, the advent of regenerative medicines, including stem cell therapy and gene editing techniques, offers promising solutions for debilitating neurological conditions. Furthermore, the increasing adoption of neurostimulation devices, such as deep brain stimulators and transcranial magnetic stimulators, is transforming the way neurological disorders are managed. These trends are expected to continue shaping the market In the coming years. Despite these advancements, challenges remain, including high treatment costs, limited access to specialized care, and the need for long-term management strategies. Addressing these challenges will require collaborative efforts from industry, academia, and regulatory bodies to ensure affordable and effective treatments for neurological disorders.

What will be the Size of the Neurologic Disorders Therapeutics Market During the Forecast Period?

Request Free Sample

The market encompasses diagnostics and pharmaceutical treatments for various Central Nervous System (CNS) conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and stroke. The global market for neurologic disorders therapeutics is experiencing significant growth due to the increasing burden of disease and the demand for effective therapeutics. According to Deloitte Insights, global spending on mental health disorders, which include neuropsychiatric conditions, is projected to reach USD1 trillion by 2020. The market dynamics are influenced by factors such as patent expiration, leading to the availability of generic products, and the development of new, innovative treatments. Neurological conditions, including neurodegenerative diseases like Alzheimer's and Parkinson's, and neuropsychiatric disorders, such as anxiety and depression, continue to pose a significant challenge to healthcare systems worldwide.
Furthermore, the neurology market also includes treatments for conditions like epilepsy, multiple sclerosis, and stroke, which affect millions of people globally. Effective therapeutics for these conditions are in high demand, as they can significantly improve patients' quality of life and reduce the burden on healthcare systems. The market for neurologic disorders therapeutics is also influenced by the development of new treatments for cardiovascular diseases, cancer, and other conditions that affect the neurons and glial cells In the CNS. Pharmaceutical companies are investing heavily in research and development to bring new, innovative treatments to market, with a focus on addressing the unmet needs of patients with neurological and neuropsychiatric conditions.

How is this Neurologic Disorders Therapeutics Industry segmented and which is the largest segment?

The neurologic disorders therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Application

  CNS
  PNS


Geography

  North America

    Canada
    US


  Europe

    UK


  Asia

    China
    India


  Rest of World (ROW)

By Application Insights

The CNS segment is estimated to witness significant growth during the forecast period.

Central nervous system (CNS) disorders encompass conditions affecting the brain and spinal cord. These disorders can be categorized into functional and degenerative types. Functional disorders, which are more prevalent, include indications such as epilepsy, migraine, dizziness, insomnia, depression, anxiety, bipolar disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), and Obsessive-Compulsive Disorder (OCD). Degenerative disorders, also known as neurodegenerative diseases, involve the decline of neurons In the brain. Neurological disorders, including CNS conditions, pose a significant burden of disease and affect millions worldwide. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are particularly challenging due to their complex nature and limited effective therapeutics. Pharmaceutical companies invest heavily in research and development (R&D) to create effective therapeutics for these conditions.

Get a glance at the Neurologic Disorders Therapeutics Industry report of share of various segments Request Free Sample

The CNS segment wa

The size and share of the market is categorized based on Type (COG-133, GZ-402668, Inebilizumab, VCE-0032, Others) and Application (Clinic, Hopital, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The Relapsing Multiple Sclerosis Treatment market is expected to reach a value of USD XXX million in 2033, growing at a CAGR of XX% during the forecast period 2025-2033. The rising prevalence of multiple sclerosis and increasing awareness about treatment options are the key drivers of market growth. The market is segmented on the basis of application, type, and region. By application, the market is segmented into therapy, maintenance therapy, and others. By type, the market is segmented into disease-modifying therapies, symptomatic therapies, and others. By region, the market is segmented into North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to hold the largest market share during the forecast period, followed by Europe and Asia Pacific.

Snapshot img

Spasticity Treatment Market Size 2025-2029

The spasticity treatment market size is forecast to increase by USD 1.27 billion at a CAGR of 4.3% between 2024 and 2029.

The market is witnessing significant growth due to the increasing incidence of chronic diseases and health conditions that result in spasticity. This condition, characterized by involuntary muscle contractions, affects a large population, particularly the elderly and individuals with neurological disorders. A key trend driving market growth is the advent of neurostimulation devices, which provide effective relief from spasticity symptoms. However, the high cost associated with these treatments remains a significant challenge, limiting access for many patients. Overall, the market is expected to continue expanding as new technologies and treatment options emerge to address the unmet needs of this patient population.

What will be the Size of the Spasticity Treatment Market During the Forecast Period?

Request Free Sample

The market encompasses a range of advanced technologies and therapies aimed at managing abnormal posture, overactive reflexes, and involuntary muscle spasms resulting from various neurological conditions. These conditions, including brain injury, cerebral palsy, and chronic neuro-musculoskeletal illnesses, can lead to increased muscle tone, stiffness, clonus, and other symptoms. Despite the availability of physiotherapy, stimulatory devices, drugs, and physiotherapy centers, the market faces challenges such as inadequate reimbursement, lack of awareness, and limited access to skilled professionals. New developments In the product pipeline analysis, including novel therapeutics and healthcare expenditure, offer potential revenue pockets for market participants. Rehabilitation nurses, recreational therapists, and healthcare facilities, including hospital pharmacies, play crucial roles in the delivery of spasticity treatment.
The growing population of children with neurological disorders and the prevalence of accidents, assaults, and other causes of spasticity further expand the market's reach. Adverse effects and product approval processes pose regulatory hurdles, while the need for continuous care and the complex nature of spasticity management present ongoing challenges.

How is this Spasticity Treatment Industry segmented and which is the largest segment?

The spasticity treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Drug therapy
  Physical therapy
  Surgical treatment


End-user

  Hospitals
  Ambulatory surgical centers
  Home care settings
  Specialty clinics
  Diagnostic centers


Indication

  Cerebral palsy
  Multiple sclerosis
  Traumatic brain injury
  Others


Route Of Administration

  Oral
  Parenteral


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Type Insights

The drug therapy segment is estimated to witness significant growth during the forecast period.

Spasticity, a muscle control disorder characterized by muscle stiffness, tightness, and increased tone, affects millions of patients with neurological conditions such as spinal cord injury, stroke, and cerebral palsy. Treatment options include pharmaceutical interventions like antispasmodic agents such as baclofen and muscle relaxants, as well as non-invasive therapies such as physical therapy exercises, speech therapy, and assistive devices. Movement disorders specialists, neurologists, orthopedic interventions, and rehabilitation centers provide diagnosis and treatment. Clinical trials are ongoing to explore new innovations, including botulinum toxin injections and reimbursement policies. Insurance coverage and patient advocacy play crucial roles in ensuring equitable access to care.

Get a glance at the market report of share of various segments Request Free Sample

The drug therapy segment was valued at USD 2.97 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 36% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American region dominates The market due to the high prevalence of neurological disorders, such as multiple sclerosis, which is a leading cause of spasticity. According to the National Center for Complementary and Integrative Health, multiple sclerosis affects approximately 400,000 Americans, m

The size and share of the market is categorized based on Drug Type (Interferons, Glatiramer Acetate, Oral Therapies, Monoclonal Antibodies, Corticosteroids) and Administration Route (Oral, Injectable, Intravenous) and Therapeutic Class (Disease-Modifying Therapies, Symptomatic Therapies) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The global rare neurological disease treatment market is expected to reach a market value of USD 9.63 billion by 2033, growing at a CAGR of 6.09% from 2025 to 2033. Key drivers of this market include increasing prevalence of neurological diseases, rising demand for innovative treatments, and growing government support for research and development. Additionally, advancements in gene therapy, cell therapy, and immunotherapy are expected to open new avenues for treating rare neurological diseases. Alzheimer's disease holds the largest share in the market due to its high prevalence and lack of effective treatment options. Parkinson's disease, multiple sclerosis, Huntington's disease, and neuromuscular diseases are other major segments, and their prevalence is expected to rise as the global population ages. Geographically, North America dominates the market with the highest revenue share due to high healthcare expenditure, well-established healthcare infrastructure, and strong government support for research and development. Europe holds the second-largest share, followed by the Asia Pacific, Middle East and Africa, and South America regions. Recent developments include: , The Rare Neurological Disease Treatment Market is projected to reach USD 16.4 billion by 2032, exhibiting a CAGR of 6.09% during the forecast period (2024-2032). The market growth is attributed to increasing prevalence of rare neurological diseases, rising demand for novel therapies, and supportive government initiatives., Recent developments in the market include:, In 2023, Biogen received FDA approval for Aduhelm, the first Alzheimer's drug approved in nearly two decades., In 2022, Roche acquired Prothena Biosciences for $5.3 billion, gaining access to their pipeline of treatments for neurodegenerative diseases., Several clinical trials are underway for gene therapies and other innovative treatments for rare neurological diseases, offering hope for patients and their families., Rare Neurological Disease Treatment Market Segmentation Insights. Key drivers for this market are: Orphan drug designation incentives Rising prevalence of rare neurological diseases Technological advancements in gene therapy and precision medicine Strategic collaborations and partnerships Government initiatives for research and development. Potential restraints include: The rising prevalence of rare neurological diseases is increasing government funding for research technological advancements in gene therapy, growing demand for personalized medicine and expanding pipeline of novel therapies..

The Autoimmune Treatment Market is Segmented by Indication (Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications), Drug class (Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs, Interferons, and Other Drugs), Sales channel (Hospital Pharmacy, Online, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

The global autoimmune and inflammatory immunomodulators market is experiencing robust growth, driven by rising prevalence of autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. An aging population, increased awareness of these conditions, and advancements in immunomodulatory therapies are key contributors to this expansion. The market's substantial size, estimated at $XX billion in 2025 (assuming a reasonable market size based on similar pharmaceutical markets), is projected to exhibit a healthy Compound Annual Growth Rate (CAGR) of XX% throughout the forecast period (2025-2033). This growth is further fueled by ongoing research and development efforts leading to the introduction of novel, more effective, and targeted therapies with improved safety profiles. Competition among major pharmaceutical players such as AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer is intense, driving innovation and potentially lowering treatment costs. However, the market faces challenges including high drug prices, potential side effects of immunomodulators, and varying regulatory approvals across different regions. Segmentation by type (e.g., biologics, small molecules) and application (e.g., rheumatoid arthritis, multiple sclerosis) reveals varying growth rates, with biologics generally commanding a larger market share due to their efficacy. Geographical analysis suggests that North America and Europe currently dominate the market due to higher healthcare expenditure and advanced healthcare infrastructure. However, emerging markets in Asia-Pacific are poised for significant growth in the coming years due to rising disease prevalence and increasing healthcare investments. The market's future trajectory depends on several factors. Continued R&D investments will be critical in developing next-generation immunomodulators with enhanced efficacy and reduced adverse effects. Government initiatives aimed at improving healthcare access and affordability in developing nations will play a significant role in expanding market penetration. Furthermore, the evolving understanding of autoimmune and inflammatory diseases and the development of personalized medicine approaches will contribute to refining treatment strategies and further enhancing market growth. Competitive landscapes will continue to shift as pharmaceutical companies develop new products and explore strategic partnerships. The market’s success will also depend on the development of sustainable and cost-effective treatment strategies that address the long-term needs of patients while managing the financial burdens associated with these therapies.

Snapshot img

Neuromuscular Disease Therapeutics Market Size 2025-2029

The neuromuscular disease therapeutics market size is forecast to increase by USD 13.73 billion at a CAGR of 14.6% between 2024 and 2029.

Neuromuscular diseases (NDMs) are a group of disorders that affect the nervous and muscular systems, leading to muscle weakness, wasting, and paralysis. The neuromuscular disease therapeutics market is experiencing significant growth due to several key factors. The approval of novel therapeutics for NDMs is increasing, providing new treatment options for patients. 
Technological advances in neuromuscular disease therapy, such as gene therapy and stem cell therapy, are revolutionizing the way these conditions are treated. However, the high cost of these therapies remains a significant challenge for patients, limiting access and affordability. Despite this, the market is expected to continue growing due to the unmet medical need and the potential of these innovative treatments to improve patient outcomes.

What will be the size of Market during the forecast period?

Request Free Neuromuscular Disease Therapeutics Market Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.

End-user

  Hospitals
  Clinics
  Others


Type

  Biologics
  Small molecules


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

Which is the largest segment driving market growth?

The market share growth by the hospitals segment will be significant during the forecast period. The market is primarily driven by the large number of patients diagnosed with neuromuscular diseases, particularly in hospitals. Neuromuscular diseases, such as spinal muscular atrophy (SMA), are treated in hospitals using advanced therapies like gene therapy (Zolgensma) and drugs (nusinersen, Spinraza, and risdiplam, Evrysdi).

Get a glance at the market share of various regions. Download the PDF Sample

The hospitals segment was the largest and was valued at USD 4.17 billion in 2018. Hospitals accounted for the largest market share in 2024 due to the high volume of patients receiving treatment for neuromuscular diseases. The market is expected to continue its dominance during the forecast period as hospitals remain the primary setting for neuromuscular disease treatment and patient care. Neuromuscular diseases, which affect the neuromuscular junction, can lead to conditions like paralysis. Other therapeutic areas, such as oncology and cardiovascular disease, are also exploring neuromuscular disease therapeutics for their pipeline.

Which region is leading the market?

For more insights on the market share of various regions, Request Free Sample

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional market trends and drivers that shape the market during the forecast period. The market in North America is experiencing significant growth due to the rising prevalence of neuromuscular diseases and the availability of advanced medical technologies for their treatment. For instance, spinal muscular atrophy, a common neuromuscular disease, affects approximately 10 to 16.66 out of every 100,000 newborns in the US, with 2.0%-2.5% of the total population being carriers of the disease gene. The high fatality rate of spinal muscular atrophy and the increasing demand for effective treatments have led to extensive research and development of gene therapies for its cure. Neuromuscular diseases, such as epilepsy and Multiple Sclerosis, significantly impact the quality of life of patients. The market is driven by the development of intravenous administration drugs and medical technologies to address the unmet medical needs of patients with these conditions.

How can Technavio assist you in making critical decisions?

What is the market structure and year-over-year growth of the Neuromuscular Disease Therapeutics Market?

    Market structure


    Fragmented




    YoY growth 2024-2025


    11.6

Market Dynamics

The market represents a significant and growing segment within the healthcare industry. This market encompasses various therapeutic modalities, including anesthesia drugs, medical devices, and healthcare technology, designed to address the unique challenges posed by neuromuscular disorders. Neuromuscular disorders, such as Parkinson's disease, Alzheimer's disease, and Huntington's disease, present complex clinical scenarios requiring innovative solutions. Anesthesia plays a crucial role in managin

The global demyelinating diseases therapeutics market is projected to reach $937 million by 2033, expanding at a CAGR of 9.7% from 2025 to 2033. The increasing prevalence of demyelinating diseases such as multiple sclerosis and Guillain-Barré syndrome, coupled with the rising demand for advanced treatment options, is driving market growth. Additionally, the introduction of new and innovative therapies, including oral and injectable medications, is expected to further fuel market expansion. The market is segmented into different types of drugs, applications, and regions. Immunomodulators, immunosuppressants, and interferons are the major types of drugs used in the treatment of demyelinating diseases. Hospitals and specialty clinics are the primary application areas for these drugs. North America dominates the market, followed by Europe and Asia-Pacific. The increasing healthcare expenditure and the presence of a large patient population in these regions contribute to their dominance.